Vergara Pasquale, Altizio Savino, Falasconi Giulio, Pannone Luigi, Gulletta Simone, Della Bella Paolo
Arrhythmia Unit and Electrophysiology Laboratories, IRCCS San Raffaele Scientific Institute, Milano, Italy.
Arrhythm Electrophysiol Rev. 2021 Apr;10(1):33-37. doi: 10.15420/aer.2020.29.
Mitral valve prolapse (MVP) is the most common valvular heart disease, affecting 2-3% of the general population. Barlow's disease is a clinical syndrome characterised by MVP. Initially thought a benign condition, MVP is now recognised as a cause of sudden cardiac death and ventricular arrhythmias. The development of new imaging techniques has contributed recently to the identification of novel risk factors. Catheter ablation of ventricular arrhythmias in patients affected by MVP is traditionally considered challenging. In this review, the authors summarise the evidence on arrhythmogenesis in the context of MVP, along with risk stratification of sudden cardiac death and the available treatment options, including new catheter ablation techniques.
二尖瓣脱垂(MVP)是最常见的心脏瓣膜病,影响着2%至3%的普通人群。巴洛氏病是一种以MVP为特征的临床综合征。MVP最初被认为是一种良性疾病,现在被认为是心源性猝死和室性心律失常的一个原因。新成像技术的发展最近有助于识别新的风险因素。传统上认为,对受MVP影响的患者进行室性心律失常的导管消融具有挑战性。在这篇综述中,作者总结了MVP背景下心律失常发生的证据,以及心源性猝死的风险分层和可用的治疗选择,包括新的导管消融技术。